Department of Rheumatology, School of Health Sciences, Faculty of Medicine, University of Ioannina, Ioannina, Greece.
Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110, Ioannina, Greece.
Rheumatol Int. 2023 Sep;43(9):1751-1754. doi: 10.1007/s00296-023-05364-9. Epub 2023 Jun 15.
Relapsing polychondritis (RP) is a rare autoimmune disease characterized by inflammation of the cartilage structures of the body with typical features of auricular chondritis, nasal and ocular inflammation, audio-vestibular damage, as well as respiratory tract manifestations. It is associated with several autoimmune diseases and many other disorders. Tumor necrosis factor alpha (TNFα) inhibitors treat many chronic inflammatory disorders. They have proven effective and relatively safe in many clinical trials and observational studies. However, several autoimmune phenomena and paradoxical inflammation have been described with TNFα inhibitors, among them RP. This report presents a 43-year-old man with psoriatic arthritis treated with ABP-501 (Amgevita), an adalimumab (ADA) biosimilar and who developed RP, 8 months after the initiation of the treatment. This, is the first report of RP development during TNFα inhibitors biosimilar. We concluded that rheumatologists dealing with patients treated with TNFα inhibitors (originators or biosimilars), should be aware of several paradoxical reactions which may emerge and RP, is one of them.
复发性多软骨炎（RP）是一种罕见的自身免疫性疾病，其特征为身体的软骨结构炎症，具有典型的耳软骨炎、鼻和眼部炎症、听觉-前庭损伤以及呼吸道表现。它与几种自身免疫性疾病和许多其他疾病有关。肿瘤坏死因子-α（TNFα）抑制剂可治疗许多慢性炎症性疾病。在许多临床试验和观察性研究中，它们已被证明是有效且相对安全的。然而，已经描述了几种与 TNFα 抑制剂相关的自身免疫现象和矛盾性炎症，其中包括 RP。本报告介绍了一名 43 岁男性，患有银屑病关节炎，接受 ABP-501（Amgevita）治疗，这是一种阿达木单抗（ADA）生物类似药，在治疗开始后 8 个月发生 RP。这是首例 TNFα 抑制剂生物类似药治疗期间发生 RP 的报告。我们得出结论，治疗接受 TNFα 抑制剂（原研药或生物类似药）治疗的患者的风湿病学家应注意可能出现的几种矛盾反应，其中包括 RP。
